{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T20:07:32Z","timestamp":1774382852016,"version":"3.50.1"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jgar.2018.03.005","type":"journal-article","created":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T19:07:21Z","timestamp":1521832041000},"page":"111-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Helicobacter pylori therapy and clinical perspective"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5209-6436","authenticated-orcid":false,"given":"Amin","family":"Talebi Bezmin Abadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Yamaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2018.03.005_bib0005","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/gut.26.11.1183","article-title":"Campylobacter pyloridis in peptic ulcer disease: microbiology, pathology, and scanning electron microscopy","volume":"26","author":"Price","year":"1985","journal-title":"Gut"},{"key":"10.1016\/j.jgar.2018.03.005_bib0010","first-page":"83","article-title":"Original isolation of Campylobacter pyloridis from human gastric mucosa","volume":"25","author":"Marshall","year":"1984","journal-title":"Microbios Lett"},{"key":"10.1016\/j.jgar.2018.03.005_bib0015","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.3748\/wjg.v23.i16.2870","article-title":"Strategies used by Helicobacter pylori to establish persistent infection","volume":"23","author":"Abadi","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0020","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1017\/erm.2017.4","article-title":"Helicobacter pylori as an oncogenic pathogen, revisited","volume":"19","author":"Miftahussurur","year":"2017","journal-title":"Expert Rev Mol Med"},{"issue":"Suppl. 1","key":"10.1016\/j.jgar.2018.03.005_bib0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1523-5378.2011.00876.x","article-title":"Pathogenesis of Helicobacter pylori infection","volume":"16","author":"Backert","year":"2011","journal-title":"Helicobacter"},{"issue":"Suppl. 1","key":"10.1016\/j.jgar.2018.03.005_bib0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1523-5378.2010.00781.x","article-title":"Pathogenesis of Helicobacter pylori infection","volume":"15","author":"Basso","year":"2010","journal-title":"Helicobacter"},{"issue":"Suppl. 2","key":"10.1016\/j.jgar.2018.03.005_bib0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1523-5378.2007.00574.x","article-title":"Colonization and infection by Helicobacter pylori in humans","volume":"12","author":"Andersen","year":"2007","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0040","first-page":"70","article-title":"Why do we still have Helicobacter pylori in our stomachs","volume":"22","author":"Abadi","year":"2015","journal-title":"Malays J Med Sci"},{"issue":"Suppl. 1","key":"10.1016\/j.jgar.2018.03.005_bib0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1523-5378.2000.0050S1003.x","article-title":"Disease-specific Helicobacter pylori virulence factors: the unfulfilled promise","volume":"5","author":"Graham","year":"2000","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0050","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrgastro.2010.154","article-title":"Mechanisms of disease: Helicobacter pylori virulence factors","volume":"7","author":"Yamaoka","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0055","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/371503","article-title":"Pathogenesis of Helicobacter pylori-related gastroduodenal diseases from molecular epidemiological studies","volume":"2012","author":"Yamaoka","year":"2012","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.jgar.2018.03.005_bib0060","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/gut.2009.192757","article-title":"Helicobacter pylori treatment in the era of increasing antibiotic resistance","volume":"59","author":"Graham","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jgar.2018.03.005_bib0065","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/124607","article-title":"Therapy of Helicobacter pylori: present medley and future prospective","volume":"2014","author":"Talebi Bezmin Abadi","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jgar.2018.03.005_bib0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/2211352515666170216142116","article-title":"Probiotics as anti-Helicobacter pylori agent: state of the art","volume":"15","author":"Abadi","year":"2017","journal-title":"Anti Infect Agents"},{"key":"10.1016\/j.jgar.2018.03.005_bib0075","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/ijc.27965","article-title":"A new approach for elimination of gastric cancer deaths in Japan","volume":"132","author":"Asaka","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jgar.2018.03.005_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00535-013-0897-8","article-title":"Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan","volume":"49","author":"Asaka","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0085","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2183\/pjab.90.251","article-title":"Strategies for eliminating death from gastric cancer in Japan","volume":"90","author":"Asaka","year":"2014","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.jgar.2018.03.005_bib0090","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1136\/gutjnl-2012-302240","article-title":"The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention","volume":"62","author":"Lee","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jgar.2018.03.005_bib0095","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(95)90113-2","article-title":"Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection","volume":"345","author":"Bayerd\u00f6rffer","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2018.03.005_bib0100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2169\/internalmedicine.55.5937","article-title":"Regression of cecal MALT lymphoma after antibiotic treatment in a patient with Helicobacter pylori infection","volume":"55","author":"Yuge","year":"2016","journal-title":"Intern Med"},{"key":"10.1016\/j.jgar.2018.03.005_bib0105","first-page":"27","article-title":"Gastric MALT lymphoma: old and new insights","volume":"27","author":"Zullo","year":"2014","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0110","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto Global Consensus Report on Helicobacter pylori gastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jgar.2018.03.005_bib0115","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/apt.13497","article-title":"The global emergence of Helicobacter pylori antibiotic resistance","volume":"43","author":"Thung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jgar.2018.03.005_bib0120","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.3748\/wjg.v23.i35.6379","article-title":"Resistance to clarithromycin and gastroenterologist\u2019s persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization","volume":"23","author":"Abadi","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ncpgasthep1138","article-title":"New concepts of resistance in the treatment of Helicobacter pylori infections","volume":"5","author":"Graham","year":"2008","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0130","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3346\/jkms.2014.29.5.704","article-title":"Meta-analysis of first-line triple therapy for Helicobacter pylori eradication in Korea: is it time to change?","volume":"29","author":"Gong","year":"2014","journal-title":"J Korean Med Sci"},{"issue":"Suppl. 4","key":"10.1016\/j.jgar.2018.03.005_bib0135","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/jgh.12796","article-title":"Changes in the first line Helicobacter pylori eradication rates using the triple therapy\u2014a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori Study Group)","volume":"29","author":"Kawai","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jgar.2017.08.013","article-title":"Clarithromycin-based therapy of Helicobacter pylori in Iran","volume":"11","author":"Abadi","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2018.03.005_bib0145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejim.2012.07.006","article-title":"Standard triple and sequential therapies for Helicobacter pylori eradication: an update","volume":"24","author":"Zullo","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jgar.2018.03.005_bib0150","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3748\/wjg.v20.i6.1438","article-title":"A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication","volume":"20","author":"Garza-Gonz\u00e1lez","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0155","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gut.2007.125658","article-title":"The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis","volume":"56","author":"Zullo","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jgar.2018.03.005_bib0160","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jgar.2016.11.008","article-title":"Helicobacter pylori treatment: new perspectives using current experience","volume":"8","author":"Abadi","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2018.03.005_bib0165","first-page":"373","article-title":"First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines","volume":"30","author":"De Francesco","year":"2017","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0170","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1572-0241.2007.01393.x","article-title":"American College of Gastroenterology guideline on the management of Helicobacter pylori infection","volume":"102","author":"Chey","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0175","first-page":"417","article-title":"Guideline on diagnosis and treatment of H. pylori infection: report from the 6th Annual Meeting of the Japanese Society for Helicobacter Research","volume":"30","author":"Saito","year":"2000","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0180","first-page":"299","article-title":"Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline","volume":"20","author":"Hunt","year":"2011","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.jgar.2018.03.005_bib0185","first-page":"665","article-title":"Guideline reviews: Helicobacter pylori infection [in Japanese]","volume":"91","author":"Asaka","year":"2002","journal-title":"Nihon Naika Gakkai Zasshi"},{"key":"10.1016\/j.jgar.2018.03.005_bib0190","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1751-2980.2011.00529.x","article-title":"World Gastroenterology Organisation Global Guideline: Helicobacter pylori in developing countries","volume":"12","year":"2011","journal-title":"J Dig Dis"},{"key":"10.1016\/j.jgar.2018.03.005_bib0195","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2006.101634","article-title":"Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report","volume":"56","author":"Malfertheiner","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jgar.2018.03.005_bib0200","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","article-title":"Management of Helicobacter pylori infection\u2014the Maastricht IV\/Florence Consensus Report","volume":"61","author":"Malfertheiner","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jgar.2018.03.005_bib0205","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1046\/j.1365-2036.2000.00766.x","article-title":"A new highly effective short-term therapy schedule for Helicobacter pylori eradication","volume":"14","author":"Zullo","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jgar.2018.03.005_bib0210","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1473-3099(06)70627-2","article-title":"Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications","volume":"6","author":"Gerrits","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2018.03.005_bib0215","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1186\/s13063-017-2281-0","article-title":"Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial","volume":"18","author":"Lee","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.jgar.2018.03.005_bib0220","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/dkg050","article-title":"The importance of efflux pumps in bacterial antibiotic resistance","volume":"51","author":"Webber","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.03.005_bib0225","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12876-017-0579-8","article-title":"Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication","volume":"17","author":"Chang","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0230","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1523-5378.2011.00829.x","article-title":"Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days?","volume":"16","author":"Hsu","year":"2011","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0235","first-page":"357","article-title":"First- and second-line Helicobacter pylori eradication with modified sequential therapy and modified levofloxacin\u2013amoxicillin-based triple therapy","volume":"27","author":"Zullo","year":"2014","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0240","first-page":"203","article-title":"Neither 10- nor 14-day sequential treatment is better than standard triple therapy for Helicobacter pylori eradication","volume":"35","author":"Warrington","year":"2016","journal-title":"P R Health Sci J"},{"key":"10.1016\/j.jgar.2018.03.005_bib0245","first-page":"133","article-title":"Efficacy and tolerability of a third-line, levofloxacin-based, 10-day sequential therapy in curing resistant Helicobacter pylori infection","volume":"21","author":"Tursi","year":"2012","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.jgar.2018.03.005_bib0250","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(12)61579-7","article-title":"Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial","volume":"381","author":"Liou","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2018.03.005_bib0255","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3109\/00365521.2014.896409","article-title":"A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea","volume":"49","author":"Lee","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0260","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4166\/kjg.2014.64.5.260","article-title":"Ten day concomitant therapy is superior to ten day sequential therapy for Helicobacter pylori eradication [in Korean]","volume":"64","author":"Kim","year":"2014","journal-title":"Korean J Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0265","first-page":"563","article-title":"A 10-day sequential therapy for eradication of Helicobacter pylori infection in children [in Chinese]","volume":"50","author":"Huang","year":"2012","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"10.1016\/j.jgar.2018.03.005_bib0270","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/hel.12085","article-title":"Ten-day quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy","volume":"19","author":"Hsu","year":"2014","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0275","doi-asserted-by":"crossref","first-page":"e880","DOI":"10.1097\/MJT.0000000000000191","article-title":"Sequential therapy or standard triple therapy for Helicobacter pylori infection: an updated systematic review","volume":"23","author":"Feng","year":"2016","journal-title":"Am J Ther"},{"key":"10.1016\/j.jgar.2018.03.005_bib0280","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.dld.2016.05.005","article-title":"Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for Helicobacter pylori eradication: a multicenter, prospective study","volume":"48","author":"Chung","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jgar.2018.03.005_bib0285","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.3748\/wjg.v18.i19.2377","article-title":"Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection","volume":"18","author":"Choi","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jgar.2018.03.005_bib0290","article-title":"Sequential versus standard triple first-line therapy for Helicobacter pylori eradication","author":"Nyssen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jgar.2018.03.005_bib0295","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/jgh.12397","article-title":"Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults?","volume":"28","author":"Yoon","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0300","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/MCG.0b013e3181acebef","article-title":"Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability","volume":"44","author":"Paoluzi","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0305","doi-asserted-by":"crossref","first-page":"923","DOI":"10.7326\/0003-4819-148-12-200806170-00226","article-title":"Meta-analysis. sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment","volume":"148","author":"Jafri","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jgar.2018.03.005_bib0310","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1365-2036.2004.01818.x","article-title":"Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure","volume":"19","author":"De Francesco","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jgar.2018.03.005_bib0315","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1365-2036.2011.04902.x","article-title":"Randomised clinical trial: comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in na\u00efve patients","volume":"35","author":"Park","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jgar.2018.03.005_bib0320","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1523-5378.2012.00947.x","article-title":"Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains","volume":"17","author":"Molina-Infante","year":"2012","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0325","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1099\/jmm.0.072322-0","article-title":"Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study","volume":"63","author":"De Francesco","year":"2014","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0330","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f4587","article-title":"Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy","volume":"347","author":"Gatta","year":"2013","journal-title":"BMJ"},{"issue":"June","key":"10.1016\/j.jgar.2018.03.005_bib0335","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017;112:212\u201339. Erratum in: Correction: ACG clinical guideline: treatment of Helicobacter pylori infection","author":"Chey","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0340","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-2036.2001.00931.x","article-title":"Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate","volume":"15","author":"Fakheri","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jgar.2018.03.005_bib0345","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/hel.12017","article-title":"Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial","volume":"18","author":"Sardarian","year":"2013","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0350","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s12275-011-1170-6","article-title":"Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran","volume":"49","author":"Abadi","year":"2011","journal-title":"J Microbiol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0355","first-page":"303","article-title":"A randomized trial comparing four Helicobacter pylori eradication regimens: standard triple therapy, ciprofloxacin based triple therapy, quadruple and sequential therapy","volume":"31","author":"Aminian","year":"2011","journal-title":"Trop Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0360","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1523-5378.2009.00671.x","article-title":"Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing \u2018concomitant therapy\u2019 versus triple therapy for Helicobacter pylori eradication","volume":"14","author":"Essa","year":"2009","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0365","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.clinre.2013.04.003","article-title":"Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study","volume":"37","author":"Zullo","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2009.09.030","article-title":"Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection","volume":"8","author":"Wu","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0375","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/1751-2980.12559","article-title":"Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication","volume":"18","author":"Ye","year":"2017","journal-title":"J Dig Dis"},{"key":"10.1016\/j.jgar.2018.03.005_bib0380","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/07853890.2017.1294761","article-title":"Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes","volume":"49","author":"Yang","year":"2017","journal-title":"Ann Med"},{"key":"10.1016\/j.jgar.2018.03.005_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00228-017-2347-7","article-title":"Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis","volume":"74","author":"Wang","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0390","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1016\/j.clinre.2013.07.007","article-title":"Concomitant, sequential, and hybrid therapy for Helicobacter pylori: which one is the correct answer?","volume":"37","author":"Chitsaz","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0395","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/CEG.S25419","article-title":"Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori","volume":"5","author":"Gisbert","year":"2012","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0400","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4292\/wjgpt.v3.i6.103","article-title":"Is concomitant quadruple therapy for Helicobacter pylori eradication really needed for Japanese patients?","volume":"3","author":"Francesco","year":"2012","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1016\/j.jgar.2018.03.005_bib0405","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.03.043","article-title":"Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection","volume":"143","author":"Federico","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jgar.2018.03.005_bib0410","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1523-5378.2011.00823.x","article-title":"A new modified concomitant therapy for Helicobacter pylori eradication in Turkey","volume":"16","author":"Toros","year":"2011","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0415","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1365-2036.2004.02248.x","article-title":"Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies","volume":"20","author":"Fischbach","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jgar.2018.03.005_bib0420","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1365-2036.2011.04770.x","article-title":"Non\u2010bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori","volume":"34","author":"Gisbert","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jgar.2018.03.005_bib0425","doi-asserted-by":"crossref","first-page":"992","DOI":"10.4103\/0366-6999.179803","article-title":"Hybrid therapy regimen for Helicobacter pylori eradication","volume":"129","author":"Song","year":"2016","journal-title":"Chin Med J"},{"key":"10.1016\/j.jgar.2018.03.005_bib0430","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/hel.12294","article-title":"Hybrid therapy as first-line regimen for Helicobacter pylori eradication in populations with high antibiotic resistance rates","volume":"21","author":"Song","year":"2016","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0435","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1523-5378.2011.00828.x","article-title":"Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14\u2009days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days","volume":"16","author":"Hsu","year":"2011","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0440","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002104","article-title":"A randomized controlled study comparing reverse hybrid therapy and standard triple therapy for Helicobacter pylori infection","volume":"94","author":"Hsu","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jgar.2018.03.005_bib0445","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/757926","article-title":"Helicobacter pylori eradication therapies in the era of increasing antibiotic resistance: a paradigm shift to improved efficacy","volume":"2012","author":"Georgopoulos","year":"2012","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.jgar.2018.03.005_bib0450","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/gutjnl-2016-311868","article-title":"First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis","volume":"67","author":"Yeo","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jgar.2018.03.005_bib0455","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1093\/jac\/dkw220","article-title":"Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment","volume":"71","author":"Puig","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.03.005_bib0460","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1572-0241.2003.t01-1-07288.x","volume":"98","author":"Laine","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0465","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1572-0241.2006.00637.x","article-title":"Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis","volume":"101","author":"Saad","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0470","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/gutjnl-2013-306120","article-title":"Ten day sequential versus 10\u2009day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial","volume":"63","author":"Liu","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jgar.2018.03.005_bib0475","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/hel.12242","article-title":"Tailored versus triple plus bismuth or concomitant therapy as initial Helicobacter pylori treatment: a randomized trial","volume":"21","author":"Zhou","year":"2016","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0480","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3109\/00365521.2015.1037345","article-title":"Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial","volume":"50","author":"Cao","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0485","doi-asserted-by":"crossref","first-page":"225","DOI":"10.15403\/jgld.2014.1121.263.zul","article-title":"Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice","volume":"26","author":"Zullo","year":"2017","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.jgar.2018.03.005_bib0490","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/1751-2980.12498","article-title":"Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori","volume":"18","author":"Wu","year":"2017","journal-title":"J Dig Dis"},{"key":"10.1016\/j.jgar.2018.03.005_bib0495","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.7314\/APJCP.2015.16.10.4353","article-title":"High efficacy of levofloxacin\u2013dexlansoprazole-based quadruple therapy as a first line treatment for Helicobacter pylori eradication in Thailand","volume":"16","author":"Prapitpaiboon","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.jgar.2018.03.005_bib0500","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/hel.12052","article-title":"Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy","volume":"18","author":"Liao","year":"2013","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0505","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2036.1995.tb00432.x","article-title":"Only four days of quadruple therapy can effectively cure Helicobacter pylori infection","volume":"9","author":"Boer","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jgar.2018.03.005_bib0510","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1523-5378.1996.tb00003.x","article-title":"Treatment of Helicobacter pylori infection: a review of the world literature","volume":"1","author":"Der Hulst","year":"1996","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0515","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1523-5378.1999.99307.x","article-title":"Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton\u00f3pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases","volume":"4","author":"Gomoll\u00f3n","year":"1999","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0520","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(16)31409-X","article-title":"Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial","volume":"388","author":"Liou","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2018.03.005_bib0525","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrgastro.2011.84","article-title":"Helicobacter pylori eradication: a new, single-capsule bismuth-containing quadruple therapy","volume":"8","author":"Gisbert","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0530","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1523-5378.2007.00518.x","article-title":"A report card to grade Helicobacter pylori therapy","volume":"12","author":"Graham","year":"2007","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0535","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1001\/jama.282.23.2240","article-title":"Fecal and oral shedding of Helicobacter pylori from healthy infected adults","volume":"282","author":"Parsonnet","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2018.03.005_bib0540","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1473-3099(17)30005-1","article-title":"How long until routine Helicobacter pylori antimicrobial susceptibility testing?","volume":"17","author":"Montes","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2018.03.005_bib0545","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1128\/CMR.00033-06","article-title":"Helicobacter pylori detection and antimicrobial susceptibility testing","volume":"20","author":"M\u00e9graud","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2018.03.005_bib0550","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1590-8658(03)00081-1","article-title":"A clinical practice viewpoint: to culture or not to culture Helicobacter pylori?","volume":"35","author":"Zullo","year":"2003","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jgar.2018.03.005_bib0555","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/MEG.0000000000000822","article-title":"The Irish Helicobacter pylori Working Group Consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland","volume":"29","author":"Smith","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0560","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/jgh.13911","article-title":"Helicobacter pylori management in ASEAN: the Bangkok Consensus Report","volume":"3","author":"Mahachai","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0565","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.dld.2015.06.010","article-title":"Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015","volume":"47","author":"Zagari","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jgar.2018.03.005_bib0570","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.cgh.2015.02.005","article-title":"Antibiotic resistance of Helicobacter pylori among male United States veterans","volume":"13","author":"Shiota","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0575","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14787210.2016.1178065","article-title":"Helicobacter pylori therapy: a paradigm shift","volume":"14","author":"Graham","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2018.03.005_bib0580","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/hel.12031","article-title":"Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012","volume":"18","author":"Lee","year":"2013","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0585","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/mdr.2014.0019","article-title":"Evolution of amoxicillin resistance of Helicobacter pylori in vitro: characterization of resistance mechanisms","volume":"20","author":"Qureshi","year":"2014","journal-title":"Microbiol Drug Resist"},{"key":"10.1016\/j.jgar.2018.03.005_bib0590","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/hel.12046","article-title":"Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China","volume":"18","author":"Su","year":"2013","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0595","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/hel.12231","article-title":"Antimicrobial susceptibility-guided therapy versus empirical concomitant therapy for eradication of Helicobacter pylori in a region with high rate of clarithromycin resistance","volume":"21","author":"Cosme","year":"2016","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0600","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijantimicag.2014.10.019","article-title":"High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam","volume":"45","author":"Phan","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2018.03.005_bib0605","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/hel.12204","article-title":"Molecular detection of Helicobacter pylori and its antimicrobial resistance in Brazzaville, Congo","volume":"20","author":"Ngoyi","year":"2015","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0610","series-title":"Helicobacter pylori clarithromycin resistance mutations are common and associated with increased treatment failures. San Diego Helicobacter pylori Antibiotic Resistance (SD HELP) Study. Laboratory investigation","year":"2017"},{"key":"10.1016\/j.jgar.2018.03.005_bib0615","doi-asserted-by":"crossref","first-page":"9912","DOI":"10.3748\/wjg.v20.i29.9912","article-title":"Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance","volume":"20","author":"Smith","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0620","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1038\/ajg.2014.222","article-title":"Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance","volume":"109","author":"Park","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0625","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12446","article-title":"Prevalence, antibiotic resistance, and MLST typing of Helicobacter pylori in Algiers, Algeria","volume":"22","author":"Raaf","year":"2017","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124199","article-title":"The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors\u2014a nationwide study","volume":"10","author":"Liou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2018.03.005_bib0635","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1128\/AAC.34.9.1637","article-title":"In vitro selection of resistant Helicobacter pylori","volume":"34","author":"Haas","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.03.005_bib0640","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1023\/A:1005457226341","article-title":"Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy","volume":"45","author":"Dore","year":"2000","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jgar.2018.03.005_bib0645","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0924-8579(00)00286-7","article-title":"Strategies to treat patients with antibiotic resistant Helicobacter pylori","volume":"16","author":"M\u00e9graud","year":"2000","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2018.03.005_bib0650","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-2036.2002.01173.x","article-title":"High rate of post-therapeutic resistance after failure of macrolide\u2013nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study","volume":"16","author":"Peitz","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jgar.2018.03.005_bib0655","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1523-5378.2003.00145.x","article-title":"Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing","volume":"8","author":"Kim","year":"2003","journal-title":"Helicobacter"},{"key":"10.1016\/j.jgar.2018.03.005_bib0660","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10757-5","article-title":"Culture-independent metagenomics supports discovery of uncultivable bacteria within the genus Chlamydia","volume":"7","author":"Taylor-Brown","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jgar.2018.03.005_bib0665","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.04.007","article-title":"Bringing culture to bacteria","volume":"169","author":"Kvajo","year":"2017","journal-title":"Cell"},{"issue":"5 Suppl. 1","key":"10.1016\/j.jgar.2018.03.005_bib0670","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1097\/INF.0000000000001106","article-title":"Understanding bacterial isolates in blood culture and approaches used to define bacteria as contaminants: a literature review","volume":"35","author":"Hossain","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2018.03.005_bib0675","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s40064-016-1949-3","article-title":"Cultivation-independent approach for the direct detection of bacteria in human clinical specimens as a tool for analysing culture-negative samples: a prospective study","volume":"5","author":"Aguilera-Arreola","year":"2016","journal-title":"Springerplus"},{"key":"10.1016\/j.jgar.2018.03.005_bib0680","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/ismej.2015.195","article-title":"Enrichment of DNRA bacteria in a continuous culture","volume":"9","author":"van den Berg","year":"2015","journal-title":"ISME J"},{"key":"10.1016\/j.jgar.2018.03.005_bib0685","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.joen.2013.07.022","article-title":"Susceptibility of as-yet-uncultivated and difficult-to-culture bacteria to chemomechanical procedures","volume":"40","author":"Rocas","year":"2014","journal-title":"J Endod"},{"key":"10.1016\/j.jgar.2018.03.005_bib0690","first-page":"1","article-title":"Strategies for culture of \u2018unculturable\u2019 bacteria","volume":"309","author":"Vartoukian","year":"2010","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.jgar.2018.03.005_bib0695","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1128\/jcm.22.6.1007-1010.1985","article-title":"Characterization of \u2018Campylobacter pyloridis\u2019 by culture, enzymatic profile, and protein content","volume":"22","author":"Megraud","year":"1985","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0700","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/infdis\/153.4.650","article-title":"Campylobacter pyloridis and gastritis","volume":"153","author":"Marshall","year":"1986","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2018.03.005_bib0705","first-page":"336","article-title":"Detection of Campylobacter pyloridis infection","volume":"99","author":"Morris","year":"1986","journal-title":"N Z Med J"},{"key":"10.1016\/j.jgar.2018.03.005_bib0710","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12876-016-0496-2","article-title":"Management of Helicobacter pylori infections","volume":"16","author":"Abadi","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0715","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1128\/JCM.00744-09","article-title":"Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori","volume":"47","author":"Cambau","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0720","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1309\/5DTF5HT7NPLNA6J5","article-title":"Helicobacter pylori: pathology and diagnostic strategies","volume":"119","author":"Versalovic","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jgar.2018.03.005_bib0725","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijantimicag.2006.11.007","article-title":"Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility","volume":"29","author":"Cattoir","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2018.03.005_bib0730","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4292\/wjgpt.v7.i4.550","article-title":"Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori","volume":"7","author":"Yamada","year":"2016","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1016\/j.jgar.2018.03.005_bib0735","doi-asserted-by":"crossref","first-page":"716","DOI":"10.4253\/wjge.v8.i19.716","article-title":"Vonoprazan 20mg vs lansoprazole 30mg for endoscopic submucosal dissection-induced gastric ulcers","volume":"8","author":"Takahashi","year":"2016","journal-title":"World J Gastrointest Endosc"},{"key":"10.1016\/j.jgar.2018.03.005_bib0740","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/1751-2980.12398","article-title":"Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: a multicenter retrospective study in clinical practice","volume":"17","author":"Shichijo","year":"2016","journal-title":"J Dig Dis"},{"key":"10.1016\/j.jgar.2018.03.005_bib0745","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2016.12.001","article-title":"Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase III, randomized, double-blind, placebo-controlled, multicenter study","volume":"81\u201382","author":"Kinoshita","year":"2016","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.jgar.2018.03.005_bib0750","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000456072","article-title":"Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis","volume":"95","author":"Hoshino","year":"2017","journal-title":"Digestion"},{"key":"10.1016\/j.jgar.2018.03.005_bib0755","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/gutjnl-2016-311796","article-title":"Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues","volume":"66","author":"Graham","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jgar.2018.03.005_bib0760","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-015-0368-z","article-title":"Vonoprazan first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2018.03.005_bib0765","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1615092","article-title":"Effects of vonoprazan compared with esomeprazole on the healing of artificial postendoscopic submucosal dissection ulcers: a prospective, multicenter, two-arm, randomized controlled trial","volume":"2018","author":"Ishii","year":"2018","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.jgar.2018.03.005_bib0770","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/apt.13959","article-title":"CYP3A4\/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan","volume":"45","author":"Sugimoto","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jgar.2018.03.005_bib0775","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5173904","article-title":"Comment on \u2018First-line Helicobacter pylori eradication with vonoprazan, clarithromycin, and metronidazole in patients allergic to penicillin\u2019","volume":"2018","author":"Kashani","year":"2018","journal-title":"Gastroenterol Res Pract"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716518300572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716518300572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:55:07Z","timestamp":1761990907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716518300572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":155,"alternative-id":["S2213716518300572"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2018.03.005","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Helicobacter pylori therapy and clinical perspective","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2018.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}